Tobacco Toxicant Exposure — Determining Levels of [D10] Phenanthrene Tetraol in Smokers' Urine
Citation(s)
ATSDR (Agency for Toxic Substances and Disease Registry) 1990. Toxicological Profile for Polycyclic Aromatic Hydrocarbons. Acenaphthene, Acenaphthylene, Anthracene, Benzo(a)anthracene, Benzo(a)pyrene, Benzo(b)fluoranthene, Benzo(g,i,h)perylene, Benzo(k)fluoranthene, Chrysene, Dibenzo(a,h)anthracene, Fluoranthene, Fluorene, Indeno(1,2,3-c,d)pyrene, Phenanthrene, Pyrene. Prepared by Clement International Corporation, under Contract No. 205-88-0608. ATSDR/TP-90-20.
Bock, F G. and T.L. Dao. 1961. Factors affecting the polynuclear hydrocarbon level in rat mammary glands. Cancer Res. 21: 1024-1029.
BOYLAND E, SIMS P Metabolism of polycyclic compounds. 21. The metabolism of phenanthrene in rabbits and rats: dihydrodihydroxy compounds and related glucosiduronic acids. Biochem J. 1962 Sep;84:571-82.
BOYLAND E, WOLF G Metabolism of polycyclic compounds. 6. Conversion of phenanthrene into dihydroxydihydrophenanthrenes. Biochem J. 1950 Jun-Jul;47(1):64-9.
Budavari, S , M.J. O'Neil and A. Smith (Eds.). 1989. The Merck Index. Merck & Co., Inc. Rahway, NJ, pp. 1143-1144.
Chang, L H. 1943. The fecal excretion of polycyclic hydrocarbons following their administration to the rat. J.. biol. Chem. 151: 93-99.
Chaturapit S, Holder GM Studies on the hepatic microsomal metabolism of (14C) phenanthrene. Biochem Pharmacol. 1978;27(14):1865-71.
FALK HL, KOTIN P, THOMPSON S INHIBITION OF CARCINOGENESIS. THE EFFECT OF HYDROCARBONS AND RELATED COMPOUNDS. Arch Environ Health. 1964 Aug;9:169-79.
GRANT G, ROE FJ THE EFFECT OF PHENANTHRENE ON TUMOUR INDUCTION BY 3,4-BENZOPYRENE ADMINISTERED TO NEWLY BORN MICE. Br J Cancer. 1963 Jun;17:261-5.
HUGGINS C, YANG NC Induction and extinction of mammary cancer. A striking effect of hydrocarbons permits analysis of mechanisms of causes and cure of breast cancer. Science. 1962 Jul 27;137(3526):257-62.
Kennaway, E L. 1924. On the cancer-producing tars and tar-fractions. J. Ind. Hyg. 5: 462-488.
Mabey, W R., J.H. Smith, R.T. Podoll, et al. 1982. Aquatic fate process data for organic priority pollutants. U.S. Environmental Protection Agency, Office of Water Regulations and Standards, Washington, D.C. EPA 440/4-81-014.
Nørager O, Town WG, Petrie JH Analysis of the registry of toxic effects of chemical substances (RTECS) files and conversion of the data in these files for input to the environmental chemicals data and information network (ECDIN). J Chem Inf Comput Sci. 1978 Aug;18(3):134-40.
Nousiainen U, Törrönen R, Hänninen O Differential induction of various carboxylesterases by certain polycyclic aromatic hydrocarbons in the rat. Toxicology. 1984 Sep 14;32(3):243-51.
Pfeiffer, E H. 1977. Oncogenic interaction of carcinogenic and non-carcinogenic polycyclic aromatic hydrocarbons in mice. IARC Scientific Publication No. 16. Air Pollution and Cancer in Man. International Agency for Research on Cancer, Lyon, France, pp. 69-77. (Cited in ATSDR, 1990)
Rahman A, Barrowman JA, Rahimtula A The influence of bile on the bioavailability of polynuclear aromatic hydrocarbons from the rat intestine. Can J Physiol Pharmacol. 1986 Sep;64(9):1214-8.
ROE FJ, SALAMAN MH Further tests for tumour-initiating activity: N, N-di-(2-chloroethyl)-p-aminophenylbutyric acid (CB1348) as an initiator of skin tumour formation in the mouse. Br J Cancer. 1956 Jun;10(2):363-78.
ROE FJ Effect of phenanthrene on tumour-initiation by 3,4-benzopyrene. Br J Cancer. 1962 Sep;16:503-6.
Roe, F J.C. and G.A. Grant. 1964. Tests of pyrene and phenanthrene for incomplete carcinogenic and anticarcinogenic activity. Br. Emp. Cancer Campaign 41: 59-60. (Abstract) (Cited in IARC, 1983)
Salamone, M F. 1981. Toxicity of 41 carcinogenic analogs. Prog. Mutat. Res. 1: 682-685. (Cited in U.S. EPA, 1988)
Sax, N I. and R.L. Lewis (Eds.). 1987. Hawley's Condensed Chemical Dictionary, 11th ed. Van Nostrand Reinhold Company, New York, p. 895.
Scribner JD Tumor initiation by apparently noncarcinogenic polycyclic aromatic hydrocarbons. J Natl Cancer Inst. 1973 Jun;50(6):1717-9.
Simmon VF, Rosenkranz HS, Zeiger E, Poirier LA Mutagenic activity of chemical carcinogens and related compounds in the intraperitoneal host-mediated assay. J Natl Cancer Inst. 1979 Apr;62(4):911-8.
Sims P Qualitative and quantitative studies on the metabolism of a series of aromatic hydrocarbons by rat-liver preparations. Biochem Pharmacol. 1970 Mar;19(3):795-818.
STEINER PE Carcinogenicity of multiple chemicals simultaneously administered. Cancer Res. 1955 Oct;15(9):632-5.
U S. EPA (U.S. Environmental Protection Agency). 1987. Health and Environmental Effects Profile for Phenanthrene. Prepared by the Environmental Criteria and Assessment Office, Office of Health
Determining Levels of [D10] Phenanthrene Tetraol in Smokers' Urine
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
